SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited (SMSPHARMA.BO) Stock Competitors & Peer Comparison
See (SMSPHARMA.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SMSPHARMA.BO | ₹380.40 | +0.00% | 35.7B | 38.05 | ₹10.03 | +0.11% |
| CIPLA.BO | ₹1,326.30 | +0.00% | 1.1T | 24.00 | ₹56.20 | +1.19% |
| CIPLA.NS | ₹1,326.70 | +0.00% | 1.1T | 23.93 | ₹56.25 | +1.19% |
| ABBOTINDIA.BO | ₹26,342.90 | +0.00% | 561.3B | 37.18 | ₹710.49 | +1.80% |
| ABBOTINDIA.NS | ₹26,365.00 | +0.00% | 561.2B | 36.83 | ₹717.13 | +1.80% |
| GLAXO.NS | ₹2,618.20 | +0.00% | 449.3B | 44.09 | ₹60.16 | +2.04% |
| GLAXO.BO | ₹2,619.40 | +0.00% | 449.1B | 47.08 | ₹56.30 | +2.04% |
| GLAND.NS | ₹1,802.40 | +0.00% | 304.6B | 35.98 | ₹51.37 | +0.97% |
| GLAND.BO | ₹1,801.30 | +0.00% | 304.1B | 35.95 | ₹51.34 | +0.97% |
| PFIZER.NS | ₹5,084.50 | +0.00% | 235.4B | 27.57 | ₹186.63 | +3.21% |
Stock Comparison
SMSPHARMA.BO vs CIPLA.BO Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, CIPLA.BO has a market cap of 1.1T. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while CIPLA.BO trades at ₹1,326.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas CIPLA.BO's P/E ratio is 24.00. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to CIPLA.BO's ROE of +0.15%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to CIPLA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check CIPLA.BO's competition here
SMSPHARMA.BO vs CIPLA.NS Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, CIPLA.NS has a market cap of 1.1T. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while CIPLA.NS trades at ₹1,326.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas CIPLA.NS's P/E ratio is 23.93. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to CIPLA.NS's ROE of +0.15%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to CIPLA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check CIPLA.NS's competition here
SMSPHARMA.BO vs ABBOTINDIA.BO Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, ABBOTINDIA.BO has a market cap of 561.3B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while ABBOTINDIA.BO trades at ₹26,342.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas ABBOTINDIA.BO's P/E ratio is 37.18. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to ABBOTINDIA.BO's ROE of +0.38%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to ABBOTINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check ABBOTINDIA.BO's competition here
SMSPHARMA.BO vs ABBOTINDIA.NS Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, ABBOTINDIA.NS has a market cap of 561.2B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while ABBOTINDIA.NS trades at ₹26,365.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas ABBOTINDIA.NS's P/E ratio is 36.83. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to ABBOTINDIA.NS's ROE of +0.38%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to ABBOTINDIA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check ABBOTINDIA.NS's competition here
SMSPHARMA.BO vs GLAXO.NS Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, GLAXO.NS has a market cap of 449.3B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while GLAXO.NS trades at ₹2,618.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas GLAXO.NS's P/E ratio is 44.09. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to GLAXO.NS's ROE of +0.56%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to GLAXO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check GLAXO.NS's competition here
SMSPHARMA.BO vs GLAXO.BO Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, GLAXO.BO has a market cap of 449.1B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while GLAXO.BO trades at ₹2,619.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas GLAXO.BO's P/E ratio is 47.08. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to GLAXO.BO's ROE of +0.56%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to GLAXO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check GLAXO.BO's competition here
SMSPHARMA.BO vs GLAND.NS Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, GLAND.NS has a market cap of 304.6B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while GLAND.NS trades at ₹1,802.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas GLAND.NS's P/E ratio is 35.98. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to GLAND.NS's ROE of +0.09%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to GLAND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check GLAND.NS's competition here
SMSPHARMA.BO vs GLAND.BO Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, GLAND.BO has a market cap of 304.1B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while GLAND.BO trades at ₹1,801.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas GLAND.BO's P/E ratio is 35.95. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to GLAND.BO's ROE of +0.09%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to GLAND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check GLAND.BO's competition here
SMSPHARMA.BO vs PFIZER.NS Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, PFIZER.NS has a market cap of 235.4B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while PFIZER.NS trades at ₹5,084.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas PFIZER.NS's P/E ratio is 27.57. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to PFIZER.NS's ROE of +0.21%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to PFIZER.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check PFIZER.NS's competition here
SMSPHARMA.BO vs PFIZER.BO Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, PFIZER.BO has a market cap of 235.3B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while PFIZER.BO trades at ₹5,086.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas PFIZER.BO's P/E ratio is 28.06. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to PFIZER.BO's ROE of +0.21%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to PFIZER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check PFIZER.BO's competition here
SMSPHARMA.BO vs SANOFI.BO Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, SANOFI.BO has a market cap of 95.4B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while SANOFI.BO trades at ₹4,077.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas SANOFI.BO's P/E ratio is 26.81. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to SANOFI.BO's ROE of +0.42%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to SANOFI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check SANOFI.BO's competition here
SMSPHARMA.BO vs SANOFI.NS Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, SANOFI.NS has a market cap of 95.2B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while SANOFI.NS trades at ₹4,080.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas SANOFI.NS's P/E ratio is 26.73. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to SANOFI.NS's ROE of +0.42%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to SANOFI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check SANOFI.NS's competition here
SMSPHARMA.BO vs SANOFICONR.NS Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, SANOFICONR.NS has a market cap of 92.3B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while SANOFICONR.NS trades at ₹3,999.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas SANOFICONR.NS's P/E ratio is 42.40. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to SANOFICONR.NS's ROE of +0.82%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to SANOFICONR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check SANOFICONR.NS's competition here
SMSPHARMA.BO vs MARKSANS.NS Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, MARKSANS.NS has a market cap of 79.7B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while MARKSANS.NS trades at ₹174.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas MARKSANS.NS's P/E ratio is 22.15. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to MARKSANS.NS's ROE of +0.14%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to MARKSANS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check MARKSANS.NS's competition here
SMSPHARMA.BO vs MARKSANS.BO Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, MARKSANS.BO has a market cap of 79.5B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while MARKSANS.BO trades at ₹174.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas MARKSANS.BO's P/E ratio is 22.62. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to MARKSANS.BO's ROE of +0.14%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to MARKSANS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check MARKSANS.BO's competition here
SMSPHARMA.BO vs SMSPHARMA.NS Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, SMSPHARMA.NS has a market cap of 35.7B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while SMSPHARMA.NS trades at ₹380.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas SMSPHARMA.NS's P/E ratio is 38.01. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to SMSPHARMA.NS's ROE of +0.14%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to SMSPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check SMSPHARMA.NS's competition here
SMSPHARMA.BO vs SENORES.NS Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, SENORES.NS has a market cap of 35.6B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while SENORES.NS trades at ₹779.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas SENORES.NS's P/E ratio is 30.04. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to SENORES.NS's ROE of +0.13%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to SENORES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check SENORES.NS's competition here
SMSPHARMA.BO vs NGLFINE.NS Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, NGLFINE.NS has a market cap of 13.9B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while NGLFINE.NS trades at ₹2,254.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas NGLFINE.NS's P/E ratio is 39.23. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to NGLFINE.NS's ROE of +0.12%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to NGLFINE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check NGLFINE.NS's competition here
SMSPHARMA.BO vs NGLFINE.BO Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, NGLFINE.BO has a market cap of 13.8B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while NGLFINE.BO trades at ₹2,246.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas NGLFINE.BO's P/E ratio is 38.89. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to NGLFINE.BO's ROE of +0.12%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to NGLFINE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check NGLFINE.BO's competition here
SMSPHARMA.BO vs TTKHLTCARE.NS Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, TTKHLTCARE.NS has a market cap of 12.9B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while TTKHLTCARE.NS trades at ₹916.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas TTKHLTCARE.NS's P/E ratio is 21.53. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to TTKHLTCARE.NS's ROE of +0.06%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to TTKHLTCARE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check TTKHLTCARE.NS's competition here
SMSPHARMA.BO vs KOPRAN.NS Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, KOPRAN.NS has a market cap of 6.3B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while KOPRAN.NS trades at ₹128.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas KOPRAN.NS's P/E ratio is 37.94. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to KOPRAN.NS's ROE of +0.03%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to KOPRAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check KOPRAN.NS's competition here
SMSPHARMA.BO vs KOPRAN.BO Comparison February 2026
SMSPHARMA.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SMSPHARMA.BO stands at 35.7B. In comparison, KOPRAN.BO has a market cap of 6.3B. Regarding current trading prices, SMSPHARMA.BO is priced at ₹380.40, while KOPRAN.BO trades at ₹128.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SMSPHARMA.BO currently has a P/E ratio of 38.05, whereas KOPRAN.BO's P/E ratio is 37.94. In terms of profitability, SMSPHARMA.BO's ROE is +0.14%, compared to KOPRAN.BO's ROE of +0.03%. Regarding short-term risk, SMSPHARMA.BO is more volatile compared to KOPRAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for SMSPHARMA.BO.Check KOPRAN.BO's competition here